Key facts
- This page summarizes Freebird Partners LP's Form 3 filing for Comera Life Sciences Holdings, Inc..
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Jan 2024, 19:40.
Freebird Partners LP - 03 Dec 2023 Form 3 Insider Report for Comera Life Sciences Holdings, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 03 Dec 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 03 Jan 2024, 19:40:05 UTC
- Prior SEC filing
- 18 Jul 2023
- Next SEC filing
- 18 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- Freebird Partners LP, By: Freebird Investments LLC, its general partner, By: /s/ Curtis W. Huff, Chairman and President
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Freebird Partners LP filed Form 3 for Comera Life Sciences Holdings, Inc. on 03 Jan 2024.
Change
- Previous filing in this sequence was filed on 18 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMRA
holding
Common Stock, par value $0.0001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,254,776
- Date
- 03 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMRA
holding
Derivative
Common Stock Purchase Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001 per share
- Underlying amount
- 743,242
- Exercise price
- $1.23
- Footnotes
- F1, F2
CMRA
holding
Derivative
Common Stock Purchase Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001 per share
- Underlying amount
- 1,198,044
- Exercise price
- $0.6135
- Footnotes
- F1, F3
CMRA
holding
Derivative
Common Stock Purchase Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001 per share
- Underlying amount
- 513,447
- Exercise price
- $0.6135
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0001 ("Common Stock") of Comera Life Sciences Holdings, Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.
Footnote F2
Pursuant to that certain Securities Purchase Agreement dated January 2, 2023, the Company issued that certain Common Stock Purchase Warrant ("Warrant") to Freebird Partners LP, in substantially the form as the form of warrant filed as Exhibit 4.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on January 4, 2023. The Warrant became exercisable on January 4, 2023, and may be exercised through January 4, 2028, at an exercise price of $1.23 per share of Common Stock.
Footnote F3
Pursuant to that certain Securities Purchase Agreement dated July 31, 2023, the Company issued that certain Common Stock Purchase Warrant ("First Warrant") to Freebird Partners LP on July 31, 2023, in substantially the form as the form of warrant filed as Exhibit 4.1 to the as announced in the Issuer's Current Report on Form 8-K filed with the SEC on August 1, 2023. The First Warrant becomes exercisable on February 1, 2024, and may be exercised through July 31, 2028, at an exercise price of $0.6135 per share of Common Stock.
Footnote F4
Pursuant to that certain Securities Purchase Agreement dated July 31, 2023, the Company issued that certain Common Stock Purchase Warrant ("Second Warrant") to Freebird Partners LP on September 11, 2023, in substantially the form as the form of warrant filed as Exhibit 4.1 to the as announced in the Issuer's Current Report on Form 8-K filed with the SEC on August 1, 2023. The Second Warrant became exercisable on September 11, 2023, and may be exercised through September 11, 2028, at an exercise price of $0.6135 per share of Common Stock.